3 Trends In Lentivirus Development And Manufacturing

The growth of the cell and gene therapy (C& GT) space, and the increasing number of CAR-T therapies entering the market, means that the demand for lentiviral vectors (LVs) as a gene delivery tool ex vivo continues to rise. As lentivirus development and manufacturing processes advance, the industry is seeing a number of key trends emerging with the aim to improve efficiency and meet expanding requirements.

This article explores the broadening potential of cell and gene therapies, lentiviral vectors and CAR-T therapies, and growing trends in the development and manufacturing of lentiviruses, including stable cell lines, more scalable upstream options, and serum-free media options.

For an in-depth exploration of the potential challenges facing LV producers, download the “Overcoming development and manufacturing challenges with lentiviral vectors” whitepaper.